PROPULSID
LOE ApproachingNDAORALTABLET
Approved
Jul 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROPULSID (generic name unknown) is an oral small-molecule tablet approved by FDA in 1993 as a New Drug Application (NDA) sponsored by Johnson & Johnson. The exact indication and mechanism of action are not specified in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30 percentile), suggesting downsizing marketing teams and transition to generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PROPULSID currently supports zero linked job openings, reflecting a mature product in late-stage lifecycle with minimal hiring activity. Professionals joining this team should expect focus on margin protection, generic transition strategy, and operational efficiency rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on PROPULSID at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.